Protective effects of recombinant osteopontin on early brain injury after subarachnoid hemorrhage in rats*
- 1 February 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 38 (2) , 612-618
- https://doi.org/10.1097/ccm.0b013e3181c027ae
Abstract
Objective: Accumulated evidence suggests that the primary cause of poor outcome after subarachnoid hemorrhage is not only cerebral arterial narrowing but also early brain injury. Our objective was to determine the effect of recombinant osteopontin, a pleiotropic extracellular matrix glycoprotein, on early brain injury after subarachnoid hemorrhage in rats. Design: Controlled in vivo laboratory study. Setting: Animal research laboratory. Subjects: One hundred seventy-seven male adult Sprague-Dawley rats weighing 300 to 370 g. Interventions: The endovascular perforation model of subarachnoid hemorrhage was produced. Subarachnoid hemorrhage or sham-operated rats were treated with an equal volume (1 μL) of pre-subarachnoid hemorrhage intracerebroventricular administration of two dosages (0.02 and 0.1 μg) of recombinant osteopontin, albumin, or vehicle. Body weight, neurologic scores, brain edema, and blood–brain barrier disruption were evaluated, and Western blot analyses were performed to determine the effect of recombinant osteopontin on matrix metalloproteinase-9, substrates of matrix metalloproteinase-9 (zona occludens-1, laminin), tissue inhibitor of matrix metalloproteinase-1, inflammation (interleukin-1β), and nuclear factor-κB signaling pathways. Measurements and Main Results: Treatment with recombinant osteopontin prevented a significant loss in body weight, neurologic impairment, brain edema, and blood–brain barrier disruption after subarachnoid hemorrhage. These effects were associated with the deactivation of nuclear factor-κB activity, inhibition of matrix metalloproteinase-9 induction, the maintenance of tissue inhibitor of matrix metalloproteinase-1, the consequent preservation of the cerebral microvessel basal lamina protein laminin, and the tight junction protein zona occludens-1. Conclusions: These results demonstrate that recombinant osteopontin treatment is effective for early brain injury after subarachnoid hemorrhage.Keywords
This publication has 37 references indexed in Scilit:
- Thrombin Inhibition by Argatroban Ameliorates Early Brain Injury and Improves Neurological Outcomes After Experimental Subarachnoid Hemorrhage in RatsStroke, 2009
- Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1)Stroke, 2008
- Glibenclamide Reduces Inflammation, Vasogenic Edema, and Caspase-3 Activation after Subarachnoid HemorrhageJournal of Cerebral Blood Flow & Metabolism, 2008
- A new grading system evaluating bleeding scale in filament perforation subarachnoid hemorrhage rat modelJournal of Neuroscience Methods, 2007
- Continuous intracerebroventricular infusion of the competitive NMDA receptor antagonist, LY235959, facilitates escalation of cocaine self-administration and increases break point for cocaine in Sprague–Dawley rats☆Pharmacology Biochemistry and Behavior, 2007
- Role of c‐Jun N‐terminal kinase in early brain injury after subarachnoid hemorrhageJournal of Neuroscience Research, 2007
- Osteopontin: role in cell signaling and cancer progressionTrends in Cell Biology, 2006
- Global Cerebral Edema After Subarachnoid HemorrhageStroke, 2002
- Expression, roles, receptors, and regulation of osteopontin in the kidneyKidney International, 2001
- Inhibition of transcription factor NF-κB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cellsCardiovascular Research, 2001